Novel inhalable gene therapy trialled for people with cystic fibrosis

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.  

Cystic fibrosis (CF) is caused by defects in the CFTR gene, which causes a buildup of thick sticky mucus in the lungs and digestive system. It causes lung infections and gradually affects the ability to breathe. The new lentiviral vector-based gene therapy works by inserting a functioning copy of the CFTR gene in the DNA of the epithelial cells in a patient’s airway. 

At present, some people with CF respond well to relatively new treatments known as CFTR modulator medicines, which work by targeting the related CFTR protein. However, these are not an option for around 10-15% of patients. 

The aim of the new treatment being trialled, known as BI 3720931, is to improve lung function and reduce exacerbations (flare-ups, often leading to hospitalisation), for people with CF irrespective of their mutation type – including those who genetically cannot benefit from other CF therapies.

The LENTICLAIR 1 trial, which will evaluate the safety, tolerability, and efficacy of the treatment, is being conducted by biopharmaceutical company Boehringer Ingelheim in partnership with the UK Respiratory Gene Therapy Consortium (GTC) and OXB (formerly Oxford Biomedica). Around 36 men and women with cystic fibrosis will be treated at centres in the UK, France, Italy, Netherlands and Spain.

Cystic fibrosis is an inherited lifelong disease that gets worse over time. It is estimated to affect 105,000 people worldwide. There are more than 2,000 known mutations in the CFTR gene, which lead to different levels of the severity of the disease.

Lentiviral vectors are a type of gene therapy that exploit the ability of lentiviruses to infect human cells. Lentiviruses are a family of viruses that infect by inserting their genetic material into their host cell’s genome. By modifying lentiviruses, scientists have been able to use them as a vehicle to insert beneficial genes into cells. 

Professor Eric Alton, Professor of Gene Therapy and Respiratory Medicine at Imperial’s National Heart & Lung Institute, is leading the trial. He coordinates the UK CF Gene Therapy Consortium, which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College London) who are focused on translational respiratory gene therapy. He is also an Honorary Consultant Physician at the Royal Brompton Hospital, one of the UK trial centres.

Professor Alton said: “The UK CF Gene Therapy Consortium is very excited to have reached this milestone after 24 years of focused effort and in close collaboration with our funding partners. While the immediate target are those patients who are not eligible for CFTR modulators, this novel therapy has the potential to achieve long-lasting CFTR function improvement and disease modification for people with CF irrespective of their mutation type and importantly has the potential for re-dosing if needed.”

Professor Jane Davies of Imperial’s National Heart and Lung Institute, who is UK Lead Investigator for the trial, said: “It’s been incredible to witness the health benefits afforded by CFTR modulators, but those who cannot benefit from these drugs urgently need alternative treatments. We’re breaking new ground in this trial with a gene therapy which has the potential for long-lasting CFTR expression. I’d like to acknowledge the people living with CF who are prepared to give their time to trials of new drugs, without whom we’d be unable to make this sort of progress.”

In the first phase of the trial, different doses of the treatment will be given to evaluate safety, tolerability and select doses for Phase II. In the second phase, two selected doses or placebo will be given in a randomised, double-blind placebo-controlled dose expansion study to assess clinical efficacy and safety.

After completion of the 24-week trial period, trial participants will take part in a long-term follow-up study, LENTICLAIR-ON.

The trial is expected to be completed in early 2027. Additional information about the trial is available via ClinicalTrials.gov at NCT06515002.

ENDS

For more information please contact:
Samantha Rey
Media Officer
Imperial College London
T: +44 (0) 020 7594 1507
E: s.rey@imperial.ac.uk
This press release uses a labelling system developed by the Academy of Medical Sciences to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf

Notes for Editors:

1. About Imperial College London:

We are Imperial – a world-leading university for science, technology, engineering, medicine and business (STEMB), where scientific imagination leads to world-changing impact.   

As a global top ten university in London, we use science to try to understand more of the universe and improve the lives of more people in it. Across our nine campuses and throughout our Imperial Global network, our 22,000 students, 8,000 staff, and partners work together on scientific discovery, innovation and entrepreneurship. Their work navigates some of the world’s toughest challenges in global health, climate change, AI, business leadership and more.  

Founded in 1907, Imperial’s future builds on a distinguished past, having pioneered penicillin, holography and fibre optics. Today, Imperial combines exceptional teaching, world-class facilities and a habit of interdisciplinary practice to unlock scientific imagination.  

2. About the UK Respiratory Gene Therapy Consortium:

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) comprises researchers from Imperial College London and the Universities of Oxford and Edinburgh. In 2001, the groups joined together as one organisation to share expertise and funding with a single common goal of making gene therapy for CF patients a clinical reality. The GTC has undertaken six non-viral Phase 1/2a proof-of-concept studies and the first Phase 2b gene therapy trial for CF, which met its primary endpoint. In parallel, it has developed the novel lentiviral vector which will be used in this first-in-human trial. Further details and commentary can be found at www.respiratorygenetherapy.org.uk